Reslizumab: Effectiveness one month after first dose.
I. Lobato Astiarraga (Ávila, Spain), M. López Zubizarreta (Ávila, Spain), A. Andrés Porras (Ávila, Spain), J. Marcos Sierra (Ávila, Spain), J. Tenes Mayen (Ávila, Spain), R. Pajares Mediavilla (Ávila, Spain), J. Tapias Del Pozo (Ávila, Spain), J. Hernández Hernández (Ávila, Spain)
Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma
Session: Clinical and laboratory pharmacology in asthma
Session type: E-poster session
Number: 1407
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Lobato Astiarraga (Ávila, Spain), M. López Zubizarreta (Ávila, Spain), A. Andrés Porras (Ávila, Spain), J. Marcos Sierra (Ávila, Spain), J. Tenes Mayen (Ávila, Spain), R. Pajares Mediavilla (Ávila, Spain), J. Tapias Del Pozo (Ávila, Spain), J. Hernández Hernández (Ávila, Spain). Reslizumab: Effectiveness one month after first dose.. 1407
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
The effect of two month's treatment with fluticasone (F) at a dose of 500 mg per day versus fluticasone at a dose of 250 mg per day plus salmeterol (S) 100 mg per day in patients with moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 302s Year: 2002
Influence of an incentive spacer on adherence to prescribed treatment in 2-6 year old children over a 3 month period Source: Annual Congress 2007 - Childhood asthma: treatment and follow-up Year: 2007
Dose selection and pharmacokinetics of montelukast (sprinkles) in >=6 month to <2 year old asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 525s Year: 2002
Efficacy of the novel very long-acting β2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006
Superior efficacy of a low daily dose of a new fixed combination of beclometasone dipropionate/formoterol pMDI compared to an increased daily dose of BDP in moderate persistent asthma: a 3 month clinical study Source: Eur Respir J 2006; 28: Suppl. 50, 207s Year: 2006
Six month treatment with formoterol - efficacy and side effects Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
The effect of single dose inhaled budesonide on Amppc20 in patients with mild asthma: a 3 month follow up Source: Eur Respir J 2005; 26: Suppl. 49, 369s Year: 2005
Efficacy, safety and tolerability of 3 day azithromycin (A) versus 10-day conventional treatment (CT) in the treatment of children with acute asthma exacerbation (AE) Source: Eur Respir J 2005; 26: Suppl. 49, 135s Year: 2005
Efficacy and safety of VR475 (budesonide suspension delivered by the VR475 Inhalation System) as add-on treatment in patients with severe asthma (CLEARCUT Study) Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019
Safety and tolerability of the novel very long acting β2-agonist Carmoterol given as a 2μg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006
Quality of life of stable dose treatment with salmeterol/fluticasone (SFC) compared with adjustable maintenance dosing (AMD) with formoterol/budesonide (FBC) Source: Eur Respir J 2005; 26: Suppl. 49, 252s Year: 2005
Cost effectiveness of inpatient initiated varenicline tartrate (VT) plus counselling compared to counselling alone: 2 year follow-up of the Smoking Termination Opportunity for inPatients (STOP) study Source: International Congress 2016 – Emerging issues in smoking cessation and tobacco products Year: 2016
Late Breaking Abstract - Short 12-month regimen with intravenous linezolid for pre-XDR TB: treatment outcomes and 24 months follow-up results Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019
RCT Abstract - Ad26.COV2.S immunogenicity in a Phase 2 trial at different booster dose levels and schedule intervals in adults Source: Virtual Congress 2021 – Challenges of COVID-19 management at short and long-term Year: 2021
LATE-BREAKING ABSTRACT: Effectiveness of training session on the inhalation technique of the BA-pMDI Autohaler® (containing beclometasone) in daily practice. Source: Annual Congress 2013 –Improving educational programmes for patients and multidisciplinary healthcare professionals Year: 2013
Effectiveness evaluation of anti-IgE treatment at 3rd year: Real life Turkey data Source: International Congress 2016 – Asthma points to ponder Year: 2016
Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) once daily (OD) for 24 weeks in persistent asthma Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Patient-reported clinical control and peak-flow: Effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long-acting2 -agonists (LABA) in moderately severe COPD Source: Annual Congress 2011 - Disease management in specific primary care populations Year: 2011
Efficacy, safety and tolerability of 3 day azithromycin versus 10-day amoxillin/clavulanic acid in the treatment of children with pneumonia Source: Eur Respir J 2003; 22: Suppl. 45, 143s Year: 2003